Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer -- Internationally recognized clinical strategist with proven track record in translating ...
Bristol Myers Squibb is expanding a partnership with oncology organization Sarah Cannon Research Institute, tapping into SCRI ...
Bristol-Myers Squibb Company (NYSE: BMY) is one of the best undervalued stocks to buy under $50. Bristol-Myers Squibb Company ...
Bristol-Myers Squibb Company (NYSE:BMY) is included in our list of the 12 deep value stocks to invest in. On November 3, 2025 ...
Drugmaker Bristol-Myers Squibb Co (BMY.N) will globally develop, make and sell a therapy being tested by New York's ...
Management now expects full-year revenue of $47.5B to $48B, up from prior guidance, driven by strength in the growth portfolio. The EPS range for 2025 is tightened to $6.40–$6.60, maintaining the ...
Bristol-Myers Squibb Company's Q3 earnings are out - beating analysts' estimates - and for once, the stock is buoyant (in trading so far today). BMY faces significant challenges as major drugs lose ...
Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the December 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
Bristol Myers Squibb hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback